Companies › Bausch Health Americas
6 active drug programs in 30 registered trials: 16 Phase 4, 9 Phase 2, 3 Phase 3, 2 Phase 1; Immunology, Infectious disease, Oncology, Gastroenterology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| IDP-122 Lotion Topical corticosteroid (halobetasol propionate) | – | Phase 4 | Psoriasis | Nov 2026 |
| Rifaximin Bacterial DNA-directed RNA polymerase inhibitor | – | Phase 4 | Diarrhea; Hepatic Encephalopathy; Diarrhoea;Acute; Pouchitis … | Apr 2027 |
| Clindamycin Bacterial 70S ribosome inhibitor | ERCC1, ERCC2 | Phase 4 | Acne Vulgaris; Skin Infection; Infection Control / Methods; Surgical Site Infection … | Dec 2027 |
| Brodalumab Interleukin-17 receptor A antagonist | IL17RA | Phase 4 | Psoriasis; Breast Cancer | Dec 2028 |
| Larsucosterol Liver X receptor (LXR) activator | LXR | Phase 3 | Hepatitis | Nov 2027 |
| plecanatide Heat-stable enterotoxin receptor agonist | GUCY2C | Phase 2 | Functional Constipation (FC) | Oct 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03883269 | Clindamycin | Phase 4 | Acne Vulgaris | Immunology | Jun 2019 |
| NCT04043897 | Rifaximin | Phase 2 | Microscopic Colitis | Immunology | Dec 2021 |
| NCT05587036 | Rifaximin | Phase 2 | Healthy Volunteers | Immunology | Jul 2025 |
| NCT05071716 | Rifaximin | Phase 3 | Hepatic Encephalopathy | Gastroenterology | Sep 2025 |
| NCT05677282 | Rifaximin | Phase 4 | Diarrhoea;Acute | Infectious disease | Sep 2025 |
| NCT05297448 | Rifaximin | Phase 3 | Hepatic Encephalopathy | Gastroenterology | Feb 2026 |
| NCT05899140 | Clindamycin | Phase 4 | Skin Infection | Infectious disease | Mar 2026 |
| NCT07474194 | Clindamycin | Phase 4 | Infection Control / Methods | Infectious disease | Apr 2026 |
| NCT07267013 | Clindamycin | Phase 2 | Aortic Surgery | Cardiovascular | Jul 2026 |
| NCT04580472 | Clindamycin | Phase 4 | Surgical Site Infection | Infectious disease | Sep 2026 |
| NCT03987763 | IDP-122 Lotion | Phase 4 | Psoriasis | Immunology | Nov 2026 |
| NCT05398679 | Clindamycin | Phase 4 | Endocarditis Infective | Cardiovascular | Dec 2026 |
| NCT07894016 | Clindamycin | Phase 4 | Wisdom Tooth Removal | Other | Dec 2026 |
| NCT04073290 | Rifaximin | Phase 4 | Hepatic Encephalopathy | Gastroenterology | Dec 2026 |
| NCT06727422 | Rifaximin | Phase 2 | IBS (Irritable Bowel Syndrome) | Gastroenterology | Jan 2027 |
| NCT06727422 | Rifaximin | Phase 2 | IBS (Irritable Bowel Syndrome) | Gastroenterology | Jan 2027 |
| NCT07285785 | Rifaximin | Phase 4 | Diarrhea | Infectious disease | Apr 2027 |
| NCT06673329 | Brodalumab | Phase 1 | Breast Cancer | Oncology | May 2027 |
| NCT05846399 | Clindamycin | Phase 4 | Cat Bite | Infectious disease | Jul 2027 |
| NCT06312683 | Rifaximin | Phase 4 | Pouchitis | Gastroenterology | Jul 2027 |
| NCT06058572 | Rifaximin | Phase 2 | Acute Leukemia | Oncology | Aug 2027 |
| NCT06538077 | Rifaximin | Phase 4 | Hepatic Encephalopathy | Gastroenterology | Aug 2027 |
| NCT07723924 | plecanatide | Phase 2 | Functional Constipation (FC) | Gastroenterology | Oct 2027 |
| NCT06718686 | Rifaximin | Phase 1 | Dementia Alzheimer Type | Neurology | Oct 2027 |
| NCT07428538 | Larsucosterol | Phase 3 | Hepatitis | Infectious disease | Nov 2027 |
| NCT07524946 | Clindamycin | Phase 4 | Acne Vulgaris | Immunology | Dec 2027 |
| NCT07209371 | Rifaximin | Phase 2 | IgA Monoclonal Gammopathy of Undetermined Significance | Oncology | May 2028 |
| NCT05502913 | Rifaximin | Phase 2 | Metastatic Lung Cancer | Oncology | Jun 2028 |
| NCT05137119 | Clindamycin | Phase 4 | Staphylococcus Aureus Bacteremia | Infectious disease | Dec 2028 |
| NCT03240809 | Brodalumab | Phase 4 | Psoriasis | Immunology | Dec 2028 |
IR INNOVATE RESEARCH PRIVATE Swedish Orphan Biovitrum Laboratorios Silanes S.A. de C.V. Jiangsu vcare pharmaceutical technology Octapharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.